Dr. Reddy’s Laboratories has entered into active pharmaceutical ingredient (API) supply and joint development agreements with the US-based Cutis Pharma to advance several programs in Cutis Pharma’s R&D portfolio, including RM-02, RM-03, and RM-06, toward FDA approval.
This partnership has significant strategic benefits for both the entities. Dr Reddy’s breadth of expertise and international infrastructure provide great synergy to Cutis Pharma’s own R&D and commercial organisations and will be a significant catalyst in its plans to fast-track the development of three of its programs towards new drug application (NDA) filings.
Cutis Pharma is a specialty pharmaceutical company that has historically developed and distributed kits used by pharmacists to safely create compounded medications, while Dr. Reddy's Laboratories, is a multinational pharmaceutical company based in Hyderabad, Telangana in India. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1518.95 |
Dr. Reddys Lab | 6321.25 |
Cipla | 1418.25 |
Zydus Lifesciences | 990.45 |
Lupin | 1640.45 |
View more.. |